Novabay Pharmaceuticals Inc.
13F holders, Q1 2025 (March 31)18holders +2
4new positions
2sold out
$0.58avg. 13F price*
At the end of Q1 2025, 18 institutions reported holding Novabay Pharmaceuticals Inc. in their 13F filings, up 2 from Q4 2024. 4 opened new positions and 2 sold out. The largest holders were Sabby Management, LLC ($128K), C2C Wealth Management, LLC ($32K) and Geode Capital Management, LLC ($20K).
- Company
- Novabay Pharmaceuticals Inc.
- CUSIP
- 66987P409
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $134K |
| Exits | 2 | $17K |
All 13F filers, Q4 2024 → Q1 2025: 239,140 shares bought and 43,930 shares sold, net +195,210 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Sabby Management, LLC | 0.54% | New | 218,045 | $128K |
| C2C Wealth Management, LLC | 0.03% | Add +8.1% | 55,000 | $32K |
| Geode Capital Management, LLC | 0.00% | Add +6.0% | 34,996 | $20K |
| XTX Topco Ltd | 0.00% | Add +23.0% | 19,847 | $12K |
| Two Sigma Securities, LLC | 0.00% | Reduce -44.4% | 17,473 | $10K |
| Susquehanna International Group, LLP | 0.00% | New | 10,560 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.1% | 5,457 | $3K |
| UBS Group AG | 0.00% | New | 749 | $438 |
| SBI Securities Co., Ltd. | 0.00% | Add +6.0% | 53 | $31 |
| Bank of America Corp. | 0.00% | Add +2.4% | 43 | $25 |
| Morgan Stanley | 0.00% | Reduce -99.7% | 6 | $4 |
| Nvwm, LLC | 0.00% | No change | 3 | $2 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 1 | $1 |
| Allworth Financial LP | 0.00% | No change | 1 | $1 |
| Osaic Holdings, Inc. | 0.00% | New | 3 | $1 |
| Addison Advisors LLC | 0.00% | No change | 1 | $1 |
| Blue Trust, Inc. | 0.00% | No change | 2 | $1 |
| Royal Bank of Canada | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is NOVABAY PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Novabay Pharmaceuticals Inc. the manager owns.